KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin (2016 - 2025)

Emergent BioSolutions' Gross Margin history spans 15 years, with the latest figure at 42.91% for Q4 2025.

  • For Q4 2025, Gross Margin rose 351.0% year-over-year to 42.91%; the TTM value through Dec 2025 reached 56.09%, up 797.0%, while the annual FY2025 figure was 56.09%, 2137.0% up from the prior year.
  • Gross Margin reached 42.91% in Q4 2025 per EBS's latest filing, down from 62.83% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 99.75% in Q4 2021 to a low of 6.94% in Q1 2023.
  • Average Gross Margin over 5 years is 54.62%, with a median of 52.52% recorded in 2025.
  • Peak YoY movement for Gross Margin: surged 8018bps in 2021, then crashed -6701bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 99.75% in 2021, then plummeted by -51bps to 49.33% in 2022, then tumbled by -33bps to 33.08% in 2023, then increased by 19bps to 39.39% in 2024, then increased by 9bps to 42.91% in 2025.
  • Per Business Quant, the three most recent readings for EBS's Gross Margin are 42.91% (Q4 2025), 62.83% (Q3 2025), and 52.52% (Q2 2025).